**Category**: Letter to Editor

**Author**

1. Sajad Ahmad Salati, MBBS, MS , MRCS (Glasgow)

The Unaizah College of Medicine and Applied Medical Sciences, Qassim University, KSA

**Address for Correspondence**

Dr Sajad Ahmad Salati

Associate Professor of Surgery,

The Unaizah College of Medicine and Applied Medical Sciences,

Qassim University, KSA.


Email: [docsajad@yahoo.co.in](mailto:docsajad@yahoo.co.in)

Mobile: 00966530435652

Transjugular Intrahepatic Portosystemic Shunt in Budd–Chiari Syndrome

A 29-year-old female who was a known case of primary Budd–Chiari Syndrome (BCS) reported with nonspecific abdominal discomfort. She had a history of multiple variceal bleeds and had undergone placement of a transjugular intrahepatic porto-systemic shunt (TIPS) three months before this episode. She was on a follow-up regimen at a regional tertiary care center for hepatic disorders. The patient was managed conservatively because the hemodynamic and laboratory parameters were within acceptable limits. Imaging was conducted to study the status and patency of the shunt. A multiaxial CT scan of the abdomen and pelvis with oral and intravenous contrast (Figure 1: A–F) showed a heterogeneous liver and a patent TIPS stent communicating the porto-venous and systemic system. The portal vein was distended with multiple collaterals. There was neither ascites nor splenomegaly (spleen size: 26 cm). The rest of the study was unremarkable.

***Figure 1: CT Scan showing patent TIPS (red arrows) and dilated collaterals (blue arrow). A: Scout film, B: Coronal view, C: Sagittal view, D: Transverse section (without contrast), E–F: Transverse section (with contrast).***



Budd–Chiari syndrome (BCS) is a very rare condition, affecting one in one million adults. BCS is named after George Budd, a British internist, and Hans Chiari, an Austrian pathologist. BCS affects younger to middle-aged patients with a mean age of 40 years. The condition is caused by an occlusion of the hepatic venous outflow at any level from the small hepatic veins to the atriocaval junction (1). The obstruction may be thrombotic or non-thrombotic. BCS is classified as primary (75%) or secondary (25%) depending on the origin of the obstructive lesion. If the obstruction results from endoluminal venous lesion-like thrombosis, it is termed primary BCS. However, if the cause originates from neighboring structures, such as extrinsic compression or tumor invasion, it is referred to as secondary BCS (2).

Two of the hepatic veins must be blocked to cause clinically evident disease that presents with a classical triad of abdominal pain, ascites, and liver enlargement. The syndrome can be fulminant, acute, subacute, chronic, or asymptomatic. Acute or sub-acute variants with diffuse occlusion of the hepatic veins still have a high mortality rate and remain challenging to treat clinically. The transjugular intrahepatic porto-systemic shunt (TIPS) has been used in recent times successfully and safely in selected patients of BCS as a definitive treatment or as successful bridge to liver transplant (3, 4). The most common indications for TIPS in BCS patients include progressive liver failure, refractory ascites, recurrent variceal bleeding, and diffuse hepatic vein thrombosis, and successful TIPS insertion has been found to improve hemodynamic and clinical parameters (5).

Insertion of a TIPS involves a technique that starts with insertion of a 5 F multipurpose catheter into the hepatic vein. Angiography is performed, and the occlusion is identified. A puncture needle is advanced into the portal vein through the liver parenchyma from the inferior vena cava (IVC), and then the guide wire is placed into the portal vein (PV) through the 10 F sheath. Portal vein angiography is performed, and the portal vein pressure and right atrium pressure are measured to calculate the porto-systemic pressure gradient (PSG). The TIPS shunt is dilated with an angioplasty balloon of 8 or 10 mm in diameter, and then a covered stent with a diameter of 8 or 10 mm is deployed (6). In a recent study, Qi X. documented procedure-related complications in up to 56% of cases after TIPS insertion and shunt dysfunction in 18–100% of cases. The short- and long-term prognosis of BCS-TIPS patients has been found to be excellent, with a one-year cumulative survival rate of 80–100% and a five-year cumulative survival rate of 74–78% (5).

**References**

1. Horton JD, San Miguel FL, Membreno F, Wright F, Paima J, Foster P, Ortiz JA. Budd-Chiari syndrome: illustrated review of current management. Liver Int. 2008; 28(4):455-66. doi: 10.1111/j.1478-3231.2008.01684.x.
2. Aydinli M, Yusuf Bayraktar Y .Budd-Chiari syndrome: Etiology, pathogenesis and diagnosis. World J Gastroenterol. 2007; 13(19): 2693–2696. doi: 10.3748/wjg.v13.i19.2693
3. Fox MA, Fox JA, Davies MH. Budd-Chiari syndrome-a review of the diagnosis and management. Acute Med. 2011; 10(1):5-9. doi: 10.1111/j.1478-3231.2008.01684.x
4. Olliff SP. Transjugular intrahepatic portosystemic shunt in the management of Budd Chiari syndrome. Eur J Gastroenterol Hepatol. 2006; 18(11):1151-4. doi: 10.1097/01.meg.0000236874.75601.a1
5. Qi X, Yang M, Fan D, Han G. Transjugular intrahepatic portosystemic shunt in the treatment of Budd-Chiari syndrome: a critical review of literatures. Scand J Gastroenterol. 2013; 48(7):771-84. doi: 10.3109/00365521.2013.777775.
6. He F , Zhao H, Dai S, Wu Y, Wang L, et al. Transjugular intrahepatic portosystemic shunt for Budd–Chiari syndrome with diffuse occlusion of hepatic veins. Sci Rep. 2016; 6: 36380. ; doi: 10.1038/srep36380